title: Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.
abstract: Hepatosplenic gammadelta T-cell lymphoma (HS-gammadeltaTCL) is an uncommon type of peripheral T-cell lymphoma, which has been associated in some cases with immunosuppression, mainly after solid organ transplants. We describe a case of HSgammadeltaTCL with a leukaemic course in a patient with Crohn's disease who had received azathioprine during the previous 5.5 years. Sinusoidal infiltration by atypical lymphocytes was observed in the liver, spleen and bone marrow and the typical cytogenetic abnormalities (isochromosome 7 and trisomy 8) were found. The patient did not respond to intensive chemotherapy. This case shows the importance of ruling out HSgammadeltaTCL in patients with hepatosplenomegaly, B-symptoms and any immunosuppressive condition.
authors.affiliation: Department of Haematology, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: José-Tomás
authors.initials: JT
authors.lastname: Navarro
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
authors.forename: José-Luis
authors.initials: JL
authors.lastname: Mate
authors.forename: Isabel
authors.initials: I
authors.lastname: Granada
authors.forename: Jordi
authors.initials: J
authors.lastname: Juncà
authors.forename: Montserrat
authors.initials: M
authors.lastname: Batlle
authors.forename: Fuensanta
authors.initials: F
authors.lastname: Millá
authors.forename: Evarist
authors.initials: E
authors.lastname: Feliu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004338:Drug Combinations; D017809:Fatal Outcome; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D012460:Sulfasalazine / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000305:Adrenal Cortex Hormones; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D016692:Receptors, Antigen, T-Cell, gamma-delta; C028423:Salazopyrine; D012460:Sulfasalazine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001379:Azathioprine; D005944:Glucosamine; D011241:Prednisone